Myasthenia gravis market to reach $10.3bn across 7MM by 2034
The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
Vutrisiran marks first silencer approved for ATTR-CM
Transthyretin amyloidosis (ATTR) is a protein conformational disorder caused by the build-up of transthyretin, the protein carrying thyroxine and retinol…
-
EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for…
-
Solid tumours: CAR-T therapies鈥� Waterloo
CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success has not yet…
-
Genentech to onshore US manufacturing amid rising drug pricing tensions
Genentech (San Francisco, CA) has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in Holly…
-
UK biopharma innovator venture financing surges to $1.1bn in Q1 2025
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value…
-
ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
On 20 May at the American Thoracic Society (ATS) 2025 conference in San Francisco, investigators from the 色界吧 Group, a…
-
ATS 2025: GSK strengthens argument for twice-annual depemokimab
On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline…
-
China鈥檚 mAb and ADC licensing was 3xUS’s in 2024 鈥� will trade tensions slow it?
China鈥檚 biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug…
-
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new…